APGE (STOCKS)
Apogee Therapeutics, Inc. Common Stock
$86.190000
-2.140000 (-2.42%)
Prev close: $88.330000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Michael Henderson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,497.81M
- Employees
- 196
- P/E (TTM)
- -20.41
- P/B (TTM)
- 5.27
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $305.27M |
| Research and Development | $229.14M |
| Other Operating Expenses | $76.13M |
| Operating Income/Loss | -$305.27M |
| Income/Loss From Continuing Operations After Tax | -$274.62M |
| Income/Loss From Continuing Operations Before Tax | -$274.34M |
| Income Tax Expense/Benefit | $274.00K |
| Net Income/Loss | -$274.62M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$274.62M |
| Net Income/Loss Available To Common Stockholders, Basic | -$274.62M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.33 |
| Diluted Earnings Per Share | -$4.33 |
| Basic Average Shares | 189,093,433 |
| Diluted Average Shares | 189,093,433 |
| Assets | $1.29B |
| Current Assets | $1.07B |
| Noncurrent Assets | $219.86M |
| Fixed Assets | $5.28M |
| Other Non-current Assets | $214.58M |
| Liabilities | $37.86M |
| Current Liabilities | $32.95M |
| Accounts Payable | $1.24M |
| Wages | $6.25M |
| Other Current Liabilities | $25.46M |
| Noncurrent Liabilities | $4.91M |
| Equity | $1.26B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.26B |
| Liabilities And Equity | $1.29B |
| Net Cash Flow From Operating Activities | -$234.54M |
| Net Cash Flow From Operating Activities, Continuing | -$234.54M |
| Net Cash Flow From Investing Activities | -$227.91M |
| Net Cash Flow From Investing Activities, Continuing | -$227.91M |
| Net Cash Flow From Financing Activities | $807.04M |
| Net Cash Flow From Financing Activities, Continuing | $807.04M |
| Net Cash Flow | $344.59M |
| Net Cash Flow, Continuing | $344.59M |
| Comprehensive Income/Loss | -$276.05M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$276.44M |
| Other Comprehensive Income/Loss | -$66.46M |